Sign in
Taking people in United StatesNo phase

Imaging brain cannabinoid receptors with PET scans in several conditions

Uses PET brain scans with OMAR to measure cannabinoid receptors in healthy people and others.

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Registry title
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Status
Recruiting
People taking part
100 people, planned
Started
Jul 2010
Expected to end
Dec 2026
Type of study
Observational, 7 groups
Treatments tested
  • [11-C]OMAR
Record updated
27 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 18-55 for brain imaging of cannabinoid receptors. Healthy men and men from several condition groups can join.

Age
18 to 55 years
Sex
Men only
Disease stage
Groups named in the record: cannabis use disorder, schizophrenia or schizoaffective disorder, prodromal syndrome for psychotic illness, first degree relative with alcoholism, PTSD, opioid use disorder, and healthy volunteers.
Earlier treatment
Cannabis users must be willing to stop cannabis use for four weeks.

Main reasons for not taking part

  • Current neuro-psychiatric illness or severe systemic disease, apart from the condition of the person's own group
  • Metal in the body that reacts to magnets, or a heart pacemaker
  • Earlier radiation exposure that, with the study tracer, would go over the exposure limits
  • Fear of closed spaces (claustrophobia)

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Males ages 18-55
  • For cannabis users:
  • Willing to abstain from cannabis use for four weeks
  • For schizophrenia:
  • Meets DSM-IV-TR criteria for schizophrenia or schizoaffective disorder
  • For prodrome for psychotic illness:
  • Meets SIPS criteria for prodromal syndrome
  • For family history positive:
  • First degree relative with alcoholism
  • For Post-Traumatic Stress Disorder
  • Meets DSM-IV-TR criteria for PTSD
  • For OUD
  • Meets DSM-IV-TR criteria for Opioid Use Disorder

Who cannot take part

  • Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
  • Current neuro-psychiatric illness (including cannabis dependence) or severe systemic disease. Cannabis use disorder is permitted in the cannabis dependent group. Schizophrenia and schizoaffective disorder is permitted in the schizophrenia group. Psychotic symptoms are permitted in the prodromal group. Post-Traumatic Stress Disorder is permitted in the PTSD group and Opioid Use Disorder is permitted in the OUD group
  • Presence of ferromagnetic metal in the body or heart pacemaker
  • Are claustrophobic

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • Connecticut Mental Health Center, Clinical Neuroscience Research UnitNew Haven, United StatesContact: Alex Selloni, BATaking people

About the trial

What the trial wants to find out

The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, [11C]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric disorders becomes available.

Read full original descriptionShow less

Those in the cannabis us disorder arm of the study will have a PET scan on at least three occasions: once while smoking as usual, once after 48-hours of abstinence from cannabis, and a final time after 4 weeks of abstinence. Additional scans may be conducted within the 4 weeks and the last scan may be conducted well beyond 4 weeks. Similarly, while most schizophrenia patients may get scanned just once, a subgroup of patients may get scanned more than once. For example to tease out the effects of medications, unmedicated patients may get scanned while unmedicated and again after treatment with antipsychotic medications. Similarly prodromes may get scanned while in the prodromal stage off medications, on medications and after conversion to schizophrenia.

The 7 groups in the trial

  • Schizophrenia

    Patients diagnosed with schizophrenia both on medication and off medication

    Treatment: [11-C]OMAR

  • Cannabis dependence

    Frequent users of cannabis

    Treatment: [11-C]OMAR

  • Family history of alcoholism

    Healthy volunteers with a first degree relative with alcoholism

    Treatment: [11-C]OMAR

  • Prodrome for psychotic illness

    Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms

    Treatment: [11-C]OMAR

  • Healthy Volunteers

    Healthy volunteers with no current or past major medical or psychiatric history

    Treatment: [11-C]OMAR

  • PTSD-Post Traumatic Stress Disorder

    Patients diagnosed with Post Traumatic Stress Disorder

    Treatment: [11-C]OMAR

  • Opioid Use Disorder

    Patients diagnosed with Opioid Use Disorder

    Treatment: [11-C]OMAR

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Characterization of CB1 Receptors Using [11-C]OMAR
Plain-language title
Imaging brain cannabinoid receptors with PET scans in several conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT01730781, who can take part
Record updated
27 April 2026